Dermatologic Reactions to Immune Checkpoint Inhibitors
Sign Up to like & getrecommendations! Published in 2017 at "American Journal of Clinical Dermatology"
DOI: 10.1007/s40257-017-0336-3
Abstract: The development of immune checkpoint inhibitors [monoclonal antibodies targeting cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), programmed cell death protein 1 (PD-1) or programmed death ligand 1 (PD-L1)] represents a major breakthrough in cancer therapy. Although they… read more here.
Keywords: immune checkpoint; dermatologic reactions; checkpoint inhibitors; iraes ... See more keywords